{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-22-071607","form_type":"8-K","ticker":"ORMP","cik":"0001176309","company_name":"ORAMED PHARMACEUTICALS INC.","filed_at":"2022-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:49.830745+00:00","generated_at":"2026-06-21T19:32:39.956387+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Oramed licenses oral insulin (ORMD-0801) to Medicox for South Korea; up to $18M milestones plus 15% royalties","bullets":["Exclusive 10-year license for ORMD-0801 in South Korea.","Up to $18M in developmental milestones; $2M already received.","Up to 15% royalties on gross sales; Medicox funds regulatory approval.","Medicox also pays transfer price per capsule; distribution targets agreed."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-22-071607","json":"https://secwatch.observer/filing/0001213900-22-071607.json","markdown":"https://secwatch.observer/filing/0001213900-22-071607.md","text":"https://secwatch.observer/filing/0001213900-22-071607.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1176309/000121390022071607/0001213900-22-071607-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1176309/000121390022071607/ea168587-8k_oramed.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T19:32:39.956387+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}